Bioengineering in organ transplantation: Targeting the liver

K. Fukumitsu, Hiroshi Yagi, A. Soto-Gutierrez

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

About 27,000 deaths are registered annually in the United States due to liver disease. At this time, the only definitive treatment of hepatic failure is orthotopic transplantation. However, there is a critical shortage of organs with the total waiting list for all organs currently at 100,000 requests. The number is increasing by 5% every year. Given that only organs in pristine condition are transplantable and that the hidden demand for organs as an anti-aging solution will be many times the current figures, orthotopic transplantation will always remain a limited pool. The increasing donor organ shortage requires consideration of alternative emerging technologies. Regenerative medicine may offer novel strategies to treat patients with end-stage organ failure. The ultimate aim of cell transplantation, tissue engineering, and stem cells is to regenerate tissues and organs. With the development of whole organ decellularization methods, the equation of organ shortage may dramatically change in the near future. Decellularized organs provide the ideal transplantable scaffold with all the necessary microstructure and extracellular cues for cell attachment, differentiation, vascularization, and function. New techniques to re-engineer organs may have major implications for the fields of drug discovery, regeneration biology, and ultimately organ transplantation. In this review we have provided an overview of complementary approaches to study and enhance the success of organ repopulation strategies creating new grafts/organs for transplantation.

Original languageEnglish
Pages (from-to)2137-2138
Number of pages2
JournalTransplantation Proceedings
Volume43
Issue number6
DOIs
Publication statusPublished - 2011 Jul

Fingerprint

Bioengineering
Organ Transplantation
Transplantation
Regenerative Medicine
Waiting Lists
Liver
Cell Transplantation
Liver Failure
Drug Discovery
Tissue Engineering
Treatment Failure
Cues
Liver Diseases
Regeneration
Cell Differentiation
Stem Cells
Tissue Donors
Technology
Transplants

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Bioengineering in organ transplantation : Targeting the liver. / Fukumitsu, K.; Yagi, Hiroshi; Soto-Gutierrez, A.

In: Transplantation Proceedings, Vol. 43, No. 6, 07.2011, p. 2137-2138.

Research output: Contribution to journalArticle

Fukumitsu, K. ; Yagi, Hiroshi ; Soto-Gutierrez, A. / Bioengineering in organ transplantation : Targeting the liver. In: Transplantation Proceedings. 2011 ; Vol. 43, No. 6. pp. 2137-2138.
@article{566f97123066494094de1b3eb6cae567,
title = "Bioengineering in organ transplantation: Targeting the liver",
abstract = "About 27,000 deaths are registered annually in the United States due to liver disease. At this time, the only definitive treatment of hepatic failure is orthotopic transplantation. However, there is a critical shortage of organs with the total waiting list for all organs currently at 100,000 requests. The number is increasing by 5{\%} every year. Given that only organs in pristine condition are transplantable and that the hidden demand for organs as an anti-aging solution will be many times the current figures, orthotopic transplantation will always remain a limited pool. The increasing donor organ shortage requires consideration of alternative emerging technologies. Regenerative medicine may offer novel strategies to treat patients with end-stage organ failure. The ultimate aim of cell transplantation, tissue engineering, and stem cells is to regenerate tissues and organs. With the development of whole organ decellularization methods, the equation of organ shortage may dramatically change in the near future. Decellularized organs provide the ideal transplantable scaffold with all the necessary microstructure and extracellular cues for cell attachment, differentiation, vascularization, and function. New techniques to re-engineer organs may have major implications for the fields of drug discovery, regeneration biology, and ultimately organ transplantation. In this review we have provided an overview of complementary approaches to study and enhance the success of organ repopulation strategies creating new grafts/organs for transplantation.",
author = "K. Fukumitsu and Hiroshi Yagi and A. Soto-Gutierrez",
year = "2011",
month = "7",
doi = "10.1016/j.transproceed.2011.05.014",
language = "English",
volume = "43",
pages = "2137--2138",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Bioengineering in organ transplantation

T2 - Targeting the liver

AU - Fukumitsu, K.

AU - Yagi, Hiroshi

AU - Soto-Gutierrez, A.

PY - 2011/7

Y1 - 2011/7

N2 - About 27,000 deaths are registered annually in the United States due to liver disease. At this time, the only definitive treatment of hepatic failure is orthotopic transplantation. However, there is a critical shortage of organs with the total waiting list for all organs currently at 100,000 requests. The number is increasing by 5% every year. Given that only organs in pristine condition are transplantable and that the hidden demand for organs as an anti-aging solution will be many times the current figures, orthotopic transplantation will always remain a limited pool. The increasing donor organ shortage requires consideration of alternative emerging technologies. Regenerative medicine may offer novel strategies to treat patients with end-stage organ failure. The ultimate aim of cell transplantation, tissue engineering, and stem cells is to regenerate tissues and organs. With the development of whole organ decellularization methods, the equation of organ shortage may dramatically change in the near future. Decellularized organs provide the ideal transplantable scaffold with all the necessary microstructure and extracellular cues for cell attachment, differentiation, vascularization, and function. New techniques to re-engineer organs may have major implications for the fields of drug discovery, regeneration biology, and ultimately organ transplantation. In this review we have provided an overview of complementary approaches to study and enhance the success of organ repopulation strategies creating new grafts/organs for transplantation.

AB - About 27,000 deaths are registered annually in the United States due to liver disease. At this time, the only definitive treatment of hepatic failure is orthotopic transplantation. However, there is a critical shortage of organs with the total waiting list for all organs currently at 100,000 requests. The number is increasing by 5% every year. Given that only organs in pristine condition are transplantable and that the hidden demand for organs as an anti-aging solution will be many times the current figures, orthotopic transplantation will always remain a limited pool. The increasing donor organ shortage requires consideration of alternative emerging technologies. Regenerative medicine may offer novel strategies to treat patients with end-stage organ failure. The ultimate aim of cell transplantation, tissue engineering, and stem cells is to regenerate tissues and organs. With the development of whole organ decellularization methods, the equation of organ shortage may dramatically change in the near future. Decellularized organs provide the ideal transplantable scaffold with all the necessary microstructure and extracellular cues for cell attachment, differentiation, vascularization, and function. New techniques to re-engineer organs may have major implications for the fields of drug discovery, regeneration biology, and ultimately organ transplantation. In this review we have provided an overview of complementary approaches to study and enhance the success of organ repopulation strategies creating new grafts/organs for transplantation.

UR - http://www.scopus.com/inward/record.url?scp=80051683282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051683282&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2011.05.014

DO - 10.1016/j.transproceed.2011.05.014

M3 - Article

C2 - 21839215

AN - SCOPUS:80051683282

VL - 43

SP - 2137

EP - 2138

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 6

ER -